TIDMMXF
RNS Number : 3051T
The MedicX Fund Limited
02 July 2018
For immediate release
2 July 2018
MedicX Fund Limited
("MedicX Fund", "the Fund" or "the Company")
Allotment of scrip shares to Directors
and Investment Adviser and total voting rights
Members of the Company's Board of Directors elected to
participate in the Company's scrip dividend scheme in respect of
the June 2018 dividend for the quarter ended 31 March 2018, and
accordingly acquired ordinary shares of no par value in the Company
(the "Shares") as disclosed in the table below.
Shares Acquired Total Shares Percentage
Held Holding
Steve Le Page 997 59,951 0.014%
John Hearle 560 45,530 0.010%
The Directors detailed above, who elected to participate in the
Company's scrip dividend scheme, did so under an election mandate
which remains in place until revoked.
Octopus Healthcare Adviser Ltd (the Company's Investment
Adviser) also elected to participate in the Company's scrip
dividend scheme in respect of the June 2018 dividend for the
quarter ended 31 March 2018, and accordingly was allotted 44,722
Shares.
The Shares were sold out of treasury at the previously advised
scrip calculation price of 80.24 pence per share.
The acquisition of the Shares brings Octopus Healthcare Adviser
Ltd's total holding in the Company to 2,421,228 shares,
representing 0.55% of the Company's total voting rights.
All above Shares were acquired on 29 June 2018 and rank pari
passu with the Company's existing ordinary shares.
In accordance with the Financial Conduct Authority's Disclosure
and Transparency Rules, the total number of ordinary shares of the
Company in issue as at 29 June 2018 was 442,799,016 (excluding
treasury shares) with each share holding one voting right.
The above figure may be used by shareholders as the denominator
for the calculations by which they will determine if they are
required to notify their interest in, or a change to their interest
in the Company, under the Disclosure and Transparency Rules.
The Company also holds 2,903,383 ordinary shares in treasury and
has 5,071,668 ordinary shares of no par value remaining under its
block listing facility.
Copies of the documents relating to the Scrip Dividend
Alternative are available for inspection through the National
Storage Mechanism (http://www.morningstar.co.uk/uk/NSM).
End
For further information please contact:
Octopus Healthcare Adviser Ltd +44 (0) 345 0404 5555
Octopus Healthcare Group +44 (0) 20 3142 4820
Mike Adams, Executive Chairman
Buchanan +44 (0) 20 7466 5000
Charles Ryland/Henry Wilson
Information on MedicX Fund Limited
MedicX Fund Limited ("MXF", "MedicX Fund", the "Fund" or the
"Company", or together with its subsidiaries, the "Group") is the
specialist primary care infrastructure investor in modern,
purpose-built primary healthcare properties in the United Kingdom
and Ireland, listed on the London Stock Exchange, with a portfolio
comprising 166 properties.
The Investment Adviser to the Company is Octopus Healthcare
Adviser Ltd, which is part of the Octopus Healthcare group. Octopus
Healthcare invests in and develops properties as well as creating
partnerships to deliver innovative healthcare buildings to improve
the health, wealth and wellbeing of the UK. It currently manages
over GBP1.4 billion of healthcare investments across a number of
platforms, with a focus on five core areas: GP surgeries, care
homes, special education schools, retirement housing and private
hospitals. Octopus Healthcare is part of the Octopus group, a
fast-growing UK fund management business with leading positions in
several specialist sectors including healthcare property, energy,
property finance and smaller company investing. Octopus manages
GBP7.7 billion of funds for more than 50,000 retail and
institutional investors as well as supplying energy to more than
180,000 customers.
Octopus Healthcare Adviser Ltd is authorised and regulated by
the Financial Conduct Authority.
The Company's website address is www.medicxfund.com. Neither the
contents of the Company's website nor the contents of any website
accessible from hyperlinks on the Company's website (or any other
website), nor the contents of any website accessible from
hyperlinks within this announcement, are incorporated into, or form
part of, this announcement.
The Company's Legal Entity Identifier is
2138008POF35FTNFCB25
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
MSCLLFLSDTIFIIT
(END) Dow Jones Newswires
July 02, 2018 10:21 ET (14:21 GMT)
Medicx (LSE:MXF)
Historical Stock Chart
From Apr 2024 to May 2024
Medicx (LSE:MXF)
Historical Stock Chart
From May 2023 to May 2024